A5034797846- Schizophrenia research and treatment
- Cannabis and Cannabinoid Research
- Substance Abuse Treatment and Outcomes
- Bipolar Disorder and Treatment
- Alcoholism and Thiamine Deficiency
- Health, Medicine and Society
- Gambling Behavior and Treatments
- Psychoanalysis and Psychopathology Research
- Sleep and related disorders
- Alcohol Consumption and Health Effects
- Eating Disorders and Behaviors
- Neurotransmitter Receptor Influence on Behavior
- Smoking Behavior and Cessation
- Personality Disorders and Psychopathology
- Impact of Technology on Adolescents
- Child Nutrition and Feeding Issues
- Tryptophan and brain disorders
- Mental Health and Psychiatry
- Treatment of Major Depression
- Sleep and Wakefulness Research
- Pain Management and Placebo Effect
- Neurology and Historical Studies
- Pharmaceutical Practices and Patient Outcomes
- Hallucinations in medical conditions
- Digital Mental Health Interventions
Institut de Psychiatrie et Neurosciences de Paris
2014-2025
Université de Picardie Jules Verne
2018-2025
Centre National de la Recherche Scientifique
2016-2025
Hôpital Paul-Brousse
2022-2025
Electronic Product Services (Czechia)
2025
Inserm
2010-2024
Centre Hospitalier Universitaire Amiens-Picardie
2016-2024
Groupe de Recherche sur l'Alcool et les Pharmacodépendances
2016-2024
Université Paris-Saclay
2022-2024
Klinik und Poliklinik für Psychiatrie und Psychotherapie
2019-2023
The authors compared impulsivity, sensation seeking, and anhedonia in a group of schizophrenic patients with without lifetime substance abuse or dependence.Patients (N=100) schizophrenia schizoaffective disorder (per DSM-III-R criteria) were assessed the Composite International Diagnostic Interview's section on psychoactive use disorder, Positive Negative Syndrome Scale, Barratt Impulsivity Zuckerman Seeking Sensation Chapman Physical Anhedonia Scale.The mean scores for impulsivity seeking...
Some studies have found that high levels of impulsivity and sensation seeking, particularly disinhibition are associated with substance abuse in patients schizophrenia, as the general population. However, no study has assessed seeking specifically schizophrenia alcohol or dependence.We compared a group (DSM-III-R criteria) lifetime dependence (n = 34) without 66). The were using composite international diagnostic interview (CIDI) for DSM-III-R disorders, positive negative syndrome scale...
Recreational use and misuse of nitrous oxide (N2O) have increased in recent years among young people. The objective present study was to assess the frequency clinical characteristics N2O disorder (NUD) a sample health professions students. An online survey distributed Age; sex; (day/week/month/year/lifetime) use, DSM-5 criteria for NUD; history mental treatment; current antidepressant medication were systematically collected. All participants completed French version Alcohol Use Disorders...
Introduction: Since the 1990s, opioid maintenance treatments (OMTs), i.e. mostly methadone and buprenorphine, have represented therapeutic cornerstone of dependence. In France, public health strategy on dependence, identified here as 'French model', has consisted offering a facilitated access to reach large treatment coverage reduce opioid-related mortality. Areas covered: Recently, new formulation subcutaneous buprenorphine depot (Buvidal®) been approved in Europe for The place Buvidal®...
ABSTRACT Psychomotor performance has consistently been found to be altered in chronic cannabis users. Neurological soft signs (NSS) reflect neurological dysfunction involving integrative networks, especially those the cerebellum, where cannabinoid receptors are particularly concentrated. Our objective was study, for first time, NSS a group of patients with dependence compared healthy control subjects, matched age, gender and level education. All outpatients seeking treatment use substance...
There is now compelling evidence that cannabis consumption might precipitate psychosis onset. The objective of the present study was to assess role individual sensitivity psychotogenic effect in male patients with schizophrenia. lifetime diagnosis, disease and substance-use history were determined using a standardized interview 190 Of use (n=121), 44 characterized as Cannabis-sensitive (CS) if onset psychotic symptoms occurred within 1 month following initiation consumption, or marked rise...
Abstract Aims To assess recovery of alcohol-related neuropsychological deficits in a group patients with pure severe alcohol use disorder (AUD) during detoxification program using the Brief Evaluation Alcohol-Related Neuropsychological Impairment (BEARNI) test. Methods Thirty-two AUD DSM-IV criteria (24 men, mean age = 45.5 ± 6.8 years old) were assessed BEARNI 8 2 days after cessation (T1) and then reassessed within 18 (T2). The primary study endpoint was number initially impaired at T1 who...
AbstractThe adverse effects of smoking cessation in individuals with mental health disorders have been a point concern, and progress the development treatment has slow. The primary first-line treatments for are Nicotine Replacement Therapy, Bupropion, Varenicline, behavioural support. Nortriptyline Clonidine second-line used when not effective or contraindicated. Smoking medications shown to be reducing nicotine cravings withdrawal symptoms promoting among patients living disorders. However,...
An abstract is not available for this content so a preview has been provided. Please use the Get access link above information on how to content.
In France, baclofen is frequently used off-label for alcohol use disorder (AUD). Baclofen has been associated with diverse adverse events (AEs), but the causality of these AEs never properly assessed.BACLOPHONE a prospective multicenter cohort study conducted in Hauts-de-France and Normandie French regions. BACLOPHONE consists phone-based monitoring 792 patients during their first year treatment AUD. Two initial phone interviews assess medical history, current medications, substance as well...